ASTX029
ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC50: 2.7 nM) . ASTX029 has anti-cancer activity[1][2].
Product Specifications
CAS Number
[2095719-92-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; ERK
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/astx029.html
Concentration
10mM
Purity
99.86
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
ClC(C(C1=CC2=C(CN([C@H](C)C(N[C@H](CO)C3=CC(F)=CC(OC)=C3)=O)C2=O)C=C1)=N4)=CN=C4NC5CCOCC5
Molecular Formula
C29H31ClFN5O5
Molecular Weight
584.04
Precautions
H302, H315, H319, H335
References & Citations
[1]Michael Reader, et al. 6-pyrimidin-isoindole derivative as erk1/2 inhibitor. WO2018193410A1.|[2]Munck JM, et al. ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. Mol Cancer Ther. 2021 Oct;20 (10) :1757-1768.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
ERK1; ERK2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
